Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Recopharma
Watertown, Massachusetts, United States
- Ownership
- Private
- Employees
- ~5000
- Development stage
- Other
01
Overview
Recipharm achieved record-breaking €827 million in revenue for 2024, demonstrating strong commercial performance across its CDMO services.
- Modalities
- Small moleculemRNA-based drugsLive biotherapeutic productsGene therapy (viral vectors and AAV)Nucleic acid-based therapies (plasmid DNA)
- Industry
- Contract Manufacturing Organization
02
Partnerships
NewBiologix (Xcell-Eng-HEK293 cell line licensing)LenioBio (ALiCE® technology collaboration)
Beyond the preview
Go deeper on Recopharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Recopharma.